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Abstract
Background: Recent data from genome-wide chromosome conformation capture analysis indicate that the human
genome is divided into conserved megabase-sized self-interacting regions called topological domains. These
topological domains form the regulatory backbone of the genome and are separated by regulatory boundary
elements or barriers. Copy-number variations can potentially alter the topological domain architecture by deleting or
duplicating the barriers and thereby allowing enhancers from neighboring domains to ectopically activate genes
causing misexpression and disease, a mutational mechanism that has recently been termed enhancer adoption.
Results: We use the Human Phenotype Ontology database to relate the phenotypes of 922 deletion cases recorded
in the DECIPHER database to monogenic diseases associated with genes in or adjacent to the deletions. We identify
combinations of tissue-specific enhancers and genes adjacent to the deletion and associated with phenotypes in the
corresponding tissue, whereby the phenotype matched that observed in the deletion. We compare this
computationally with a gene-dosage pathomechanism that attempts to explain the deletion phenotype based on
haploinsufficiency of genes located within the deletions. Up to 11.8% of the deletions could be best explained by
enhancer adoption or a combination of enhancer adoption and gene-dosage effects.
Conclusions: Our results suggest that enhancer adoption caused by deletions of regulatory boundaries may
contribute to a substantial minority of copy-number variation phenotypes and should thus be taken into account in
their medical interpretation.
Background
Genomic deletions and duplications result in the loss or
gain of specific genomic segments and thus are referred
to as copy-number variants (CNVs). The phenotypes of
CNV disorders are often complex, commonly involv-
ing intellectual disability and multiple congenital anoma-
lies [1]. The phenotypic abnormalities seen in some
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diseases associated with CNVs are thought to be related to
altered gene dosage effects of one or more genes located
within the CNV. For instance, Williams syndrome (WS)
is a multisystem disorder that results from heterozygous
deletion of 1.5 to 1.8 Mb on chromosome 7q11.23, which
contains approximately 28 genes [2]. Some of the pheno-
typic abnormalities of WS have been attributed to hem-
izygosity of individual genes located within the deleted
region. Thus, hemizygosity for the ELN gene is thought to
cause the supravalvular aortic stenosis [4], LIMK1 hem-
izygosity is implicated in the impaired visuospatial con-
structive cognition [3] andGTF2I hemizygosity is thought
to contribute to the mental retardation inWS patients [5].
Alteration of gene dosage by deletion or duplication
or by disruption of genes located at the boundaries
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of CNVs thus represents a plausible pathomechanism
for many phenotypic abnormalities seen in CNV dis-
orders. However, structural variations such as CNVs,
inversions or translocations can also change the reg-
ulatory context of genes, thereby disturbing the del-
icate balance between enhancers, silencers and insu-
lators by interfering with the complex chromosomal
looping and interaction mechanisms of promoters and
one or more cis-regulatory elements. These changes
in the regulatory environment of genes can result in
misexpression and subsequent deregulation of signaling
[6-8].
Long-range looping interactions over tens or even
hundreds of kilobases together with three-dimensional
nuclear organization, involving the positioning of genes,
regulatory sequences and DNA binding proteins, help
determine which genes are transcribed at any given
time [9,10]. Hi-C is a method that probes the three-
dimensional architecture of whole genomes by coupling
proximity-based ligation with massively parallel, next-
generation sequencing [11]. Recently, Hi-C was used
to identify megabase-sized local chromatin interaction
regions termed ‘topological domains’; the domains rep-
resent highly self-interacting regions bounded by narrow
segments where the chromatin interactions appear to end
abruptly [12]. Topological domains were suggested to rep-
resent chromosomal units that serve to spatially accom-
modate enhancer–promoter interactions and control gene
expression levels across cell populations [13]. The bound-
ary regions between the domains are associated with
CCCTC-binding factor (CTCF) binding sites, cohesin
binding sites and active transcription of housekeeping
genes [12]. Recent knock-down experiments suggest that
CTCF and cohesin contribute differentially to chromatin
organization and gene regulation, but surprisingly deple-
tion of both was not accompanied by disruption of topo-
logical domain organization [14]. Therefore, it remains
unclear whether the observed topological domains are
the cause of genomic interaction or a consequence [15],
but the boundaries between the domains might func-
tion as regulatory barriers by inhibiting the interaction of
enhancers/silencers in one domain with genes in the adja-
cent domain [16]. Recent studies in Drosophila suggest
that insulator proteins are frequently found at topolog-
ical domain boundaries (TDBs) [17]. It was also shown
that insulators can organize and support very long-range
functional interactions between regulatory elements at
distances of up to several megabases [18,19]. Since insula-
tor proteins mediate not only enhancer blocking but also
contribute to the organization of chromosome architec-
ture and the integrity of regulatory elements, they have
been dubbed architectural proteins [17]. The role of these
architectural proteins in TDBs in vertebrates is currently
being investigated.
We recently identified the etiology of Liebenberg syn-
drome, an autosomal-dominant upper-limb malforma-
tion, as a homeotic limb transformation in which the arms
acquire morphological characteristics of a leg. We char-
acterized deletions in the vicinity of PITX1 in patients
with Liebenberg syndrome. PITX1 is a homeobox gene
that plays a role in specifying the identity or structure
of the lower limb. The structural changes are likely to
remove a barrier element that separates the PITX1 regula-
tory domain from neighboring regulators. In Liebenberg
syndrome, a highly conserved non-coding enhancer ele-
ment, hs1473, which is normally separated from PITX1
by a TDB, was relocated into the vicinity of PITX1. Ele-
ment hs1473 was shown to have forelimb-specific activity
in mouse embryos, and transgenic hs1473-Pitx1 mice
showed features characteristic of Pitx1 misexpression at
embryonic day 15.5, as well as phenotypic features of
forelimb-to-hindlimb transformation [20]. These obser-
vations suggested that the pathomechanism of Liebenberg
syndrome can best be explained by a topological domain
boundary disruption (TDBD) between an enhancer with
activity in the forelimb and a gene that is phenotypically
related to the clinical manifestations observed in individ-
uals with Liebenberg syndrome [21]. We will refer to this
phenomenon as ‘enhancer adoption’.
This observation motivated us to ask whether computa-
tional evidence can be obtained for additional CNVs with
an analogous pathomechanism by searching for a bioin-
formatic signature suggestive of enhancer adoption. Here,
we perform a systematic computational analysis of phe-
notypes of patients in the DECIPHER database [22]. Our
results suggest that a substantial proportion of CNVs are
associated with phenotypes that can be partially or com-
pletely explained by disruption of genomic barrier effects
associated with ectopic activation of phenotypically rele-
vant genes.
Results and discussion
In this work, we present a computational analysis of the
hypothesis that the disruption of TDB regions may con-
tribute to or even be the major factor of the phenotypes
observed in a subset of CNV disorders. We developed an
analysis strategy that relates the phenotypic features of the
CNV disorders to the locations of genes and TDBs within
and near to the CNV as well as the phenotypic features of
monogenic disorders affecting these genes.
Our approach involves comparing the phenotypic fea-
tures associated with the CNVs with the phenotypic fea-
tures associated with Mendelian diseases of single genes
located within or adjacent to the CNVs. To do so, we
perform semantic similarity analysis using the Human
Phenotype Ontology (HPO) as described in detail in the
Materials and methods. We define a gene as being phe-
notypically relevant if mutations in that gene lead to a
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Mendelian disease with phenotypic abnormalities that are
similar to those of the CNV disorder (such as the genes
ELN, LIMK1 and GTF2I in WS, as described above). We
analyzed 2,300 deletions in DECIPHER for which phe-
notype data were available, and found that the degree
of similarity between CNV phenotypes and phenotypes
associated with single genes located within the CNVs was
significantly higher than for random deletions (19.6±28.8
compared to 14.2±25.6; P = 8.54×10−67,Wilcoxon test).
This result suggests that our computational approach of
‘explaining’ the phenotypic features of CNVs is applicable
to the analysis of deletions in the DECIPHER database.
We reasoned that deletions whose pathomechanism
involves disruption of a TDB could be identified by
searching for a specific bioinformatic signature whereby
the deletion removes one or more TDBs and thereby
brings a tissue-specific enhancer into the vicinity of a
phenotypically relevant gene. On the other hand, CNVs
whose pathomechanism primarily involves a gene dosage
effect could be identified by the presence of one or more
phenotypically relevant genes within the CNV without
the presence of tissue-specific enhancers or relevant genes
directly surrounding the CNV. In the following, we will
refer to these categories as TDBD and gene-dosage effect
(GDE) (Figure 1).
Distribution of topological domain boundaries in
pathogenic and neutral deletions
A total of 7,535 CNV cases from the DECIPHER
database [22] were examined. The CNVs had an aver-
age size of 3.61 Mb, including 4,055 deletions, 2,300 of
which were annotated with at least one HPO term. In
this work, we concentrate on deletions. We first analyzed
the relationship of the CNVs to the TDBs. There were a
Figure 1Models of deletion pathomechanism. In each panel, an exemplary deletion is shown as a red bar, a TDB is indicated with a black arrow,
and genes associated with the phenotypes of the CNV patient are shown in blue, other genes in gray. Phenotypic abnormalities are represented as
exemplary HPO terms (HP1, HP2 and HP3). Three tissue-specific enhancers are shown in (B) as black ovals. (A) Gene-dosage effect (GDE). A deletion
leads to a reduction in the dosage of haplosensitive genes located within the CNV. The individual with the deletion has two phenotypic
abnormalities (HP1, HP2) resulting from deletion of two haplosensitive genes. A Mendelian disease related to mutations in the first gene is associated
with HP1, and a Mendelian disease related to mutations in the second gene is associated with HP2. (B) Topological domain boundary disruption
(TDBD). Removal of the topological domain boundary allows the tissue-specific enhancer inappropriately to activate a phenotypically relevant gene
located adjacent to the deletion, a phenomenon that we refer to as enhancer adoption. In this case, the individual with the deletion has a
phenotypic abnormality (HP3) that is also seen in individuals with a Mendelian disease related to a mutation in the gene adjacent to the deletion.
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total of 3,026 non-overlapping boundaries in the human
genome, encompassing a total of 134.32 Mb sequence
and corresponding to roughly one boundary per million
nucleotides of the haploid genome. Correspondingly, the
CNVs contained 3.3 boundaries on average.We compared
these figures to those obtained for a set of 1,958 deletions
derived from adult probands investigated in genome-wide
association studies by the Wellcome Trust Case Control
Consortium 2 (WTCCC2), and which we will therefore
regard as non-pathogenic control deletions in the context
of congenital disease that is the focus of our analysis in this
paper (Table 1).
Unsurprisingly, the mean size of the DECIPHER dele-
tions was substantially higher than that of the control
deletions (3.7 ± 5.0 Mb vs 0.414 ± 0.27 Mb). Of all 922
DECIPHER deletions analyzed, 72.6% overlap at least one
TDB completely. This in itself is not significantly different
from random expectation (71.6%) (Figure 2A). In con-
trast, 6.38% (125 of 1,958) of the non-pathogenic deletions
overlap at least one boundary. We estimated the expec-
tation by randomly placing equally sized deletions onto
the genome and calculating the percentage with at least
one overlapping topological domain boundary. We per-
formed 10,000 simulations in which 1,958 deletions of the
same sizes as the 1,958 original WTCCC2 deletions were
placed at random positions of the genome, which dis-
played a mean of 31.3 ± 1% deletions overlapping at least
one TDB (Figure 2B). None of the randomized data sets
have a lower or equal rate of boundary overlaps, corre-
sponding to an empirical P value of P < 10−4. Thus the
benign control CNVs are significantly underrepresented
at TDB regions. A similar analysis showed that WTCCC2
deletions overlap a lesser number of genes than would
be expected by chance (Figure 2D) and the DECIPHER
deletions overlap more genes than expected (Figure 2C).
We were therefore motivated to investigate how com-
mon TDBD is among pathological deletions associated
with congenital anomalies. However, given that the mean
size of the deletions in DECIPHER is 3.68 Mb, with over
three TDBs being removed on average, themere fact that a
pathological deletion disrupts a TDB is not surprising.We
therefore reasoned that it is necessary to take tissue speci-
ficity of enhancers as well as the phenotypic abnormalities
associated with genes within and adjacent to deletions into
account to assess the potential association of TDBD with
deletion phenotypes.
A computational phenotypic signature of topological
domain boundary disruption
We reasoned that if TDBD is responsible for the patho-
genesis of a sizable number of CNVs, then we should
be able to detect a corresponding bioinformatic signa-
ture significantly more often than would be expected by
random chance. To test this hypothesis, we developed
a strategy for predicting computationally which CNVs
are most likely to be partially or completely related to
TDBD by comparing the phenotypes of the CNVs with
the phenotypes of single-gene diseases of genes located
within or adjacent to the CNVs and comparing their dis-
tribution with that of predicted tissue-specific enhancers
(Additional file 1: Figure S2).
DNase-sequencing (DNase-seq) experiments from the
National Institutes of Health’s Roadmap Epigenomics
Mapping Consortium (NIH REMC) offer a unique
resource for identifying enhancers. DNase I hypersen-
sitivity, as measured by DNase-seq, has been used
previously to characterize human cell lines, reveal-
ing cell-type-specific promoters and enhancers [23-25].
The human genome is thought to harbor at least
400,000 enhancers [26], many of which exhibit tissue or
developmental-stage specificity [27].
While cell-type-specific DNase I hypersensitive sites
(CTS-DHSs) have been identified by the Roadmap con-
sortium [28], this previous method did not attempt to
Table 1 CNV data fromDECIPHER and control CNVs taken from theWTCCC2 study
Data n Length (Mb) HPO terms TDBs Genes
DECIPHER
CNV cases 7,535 3.61 (±7.54) 3.3 (±4.9) 3.3 (±7.6) 29.2 (±53.6)
Deletions 4,055 3.68 (±5.74) 3.6 (±4.2) 3.4 (±5.6) 27.7 (±37.6)
Deletions with phenotype data 2,300 3.7 (±5.0) 5.6 (±4.7) 3.5 (±5.2) 27.3 (±32.7)
Deletions with unique target phenotype 922 4.6 (±5.3) 7.5 (±5.1) 4.3 (±5.7) 33.3 (±35.0)
WTCCC2 Controls
Probands 5,919 0.428 (±0.29) 0.0 (±0.0) 0.099 (±0.37) 2.9 (±4.2)
Deletions 1,958 0.414 (±0.27) 0.0 (±0.0) 0.071 (±0.29) 2.3 (±2.9)
The mean value (± one standard deviation) is shown for the length of the CNV in megabases (Mb), the number of HPO terms used to annotate the CNV (only
DECIPHER), as well as the number of TDBs and the number of genes contained within the CNV.
CNV, copy-number variation/variant; HPO, Human Phenotype Ontology; Mb, megabase; TDB, topological domain boundary; WTCCC2, Wellcome Trust Case Control
Consortium 2.
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Figure 2 Non-pathogenic deletions are depleted in genes and topological domain boundaries. (A,B) Percentage of deletions that overlap at
least one topological domain boundary (TDB). (A) DECIPHER and (B)WTCCC2. Deletions are compared with randomized data in which the same
number of deletions (922 for DECIPHER and 1,958 for WTCCC2) of the same sizes as the original deletions were placed at random positions of the
genome. This randomization was performed a total of 10,000 times, and the empirical distribution of TDB overlaps is plotted as gray bars. (C,D)
Average number of genes overlapped by (C) DECIPHER and (D)WTCCC2 deletions compared with randomized data generated as in (A) and (B).
CNV, copy-number variation/variant; TDB, topological domain boundary; WTCCC2, Wellcome Trust Case Control Consortium 2.
account for within-cell-type variability, a critical step in
our methodology for generating the ranking of sites that
are consistently hypersensitive in a given tissue, relative to
an average profile of all cell types. For this work, we ana-
lyzed nine fetal tissues, two non-fetal primary cell types
and two cell lines to identify genomic regions with high
degrees of chromatin accessibility that are most specific
for certain tissues (see Materials and methods for details).
For each cell type, we determined a set of high-confidence
CTS-DHSs using reproducibility of the top-ranked sites
across replicates. As the cell types of the tissues of inter-
est all reached maxima of reproducibility for more than
20,000 sites, this led us to conclude that we could use the
top 20,000 sites for each cell type as proxies for tissue-
specific enhancers in the rest of the study (Figure 3,
Additional file 1: Figure S1 and Additional file 1: Table S1).
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Figure 3 DNase I hypersensitive sites (DHSs). (A) Tissue-specific DHSs were predicted on the basis of DNase-seq data if chromatin accessibility
was significantly higher in a given tissue than for the average over all cell types (ubiquitous DHS, black track). The vertical blue arrow indicates one of
the top fetal-brain-specific DHSs more than 30 kb proximal to a promoter of GFRA1, a glial-cell-line-derived neurotrophic factor. Tissue types are
color coded as in (B). (B) Hierarchical clustering of samples by DNase-seq profiles. The distance between samples was defined as 1 − cor(x, y).
Correlations were calculated between the log counts of DNase-seq reads in 200-bp non-overlapping windows. (C) Locations of cell-type-specific
DNase I hypersensitive sites (CTS-DHSs) and ubiquitous DHSs. The top ranked CTS-DHSs fall mostly in intronic and intergenic regions. The majority
of the top ubiquitous DHSs are in promoters. chr10, chromosome 10; CTS-DHS, cell-type-specific DHS; DHS, DNase I hypersensitive site; iPS, induced
pluripotent stem cell; kb, kilobase.
To test the hypothesis that the TDBD pathomechanism
is contributory for a subset of CNVs, we first assigned
each CNV case to one of the general target terms that
represent the ten tissues for which specific enhancers are
available (Table 2) by identifying the HPO target term
with a maximum similarity to the CNV phenotype terms.
For brevity, we will refer to these HPO terms as ‘target
phenotypes’.
In our analysis, we assigned deletions to the category
TDBD if they completely overlapped a TDB and a tissue-
specific enhancer and a phenotypically relevant gene were
identified surrounding the deletion with the enhancer and
the gene being on different sides of the deletion. A dele-
tion was assigned to the category GDE if it contained
one or more genes that were phenotypically relevant to
the CNV, that is, for which the phenogram score (see
Materials and methods) was above zero, with the addi-
tional condition that no computational evidence for
TDBD was present. Finally, a deletion was assigned to the
TDBD only category if the phenotypic similarity score of
genes adjacent to the deletion was higher than for genes
within the deletion. Note that a gene or enhancer was
Table 2 Tissue-specific enhancers and corresponding HPO terms for ten tissue types
Tissue HPO term name Term ID Descendant
terms
Genes Cases
Fetal adrenal gland Abnormality of the adrenal glands HP:0000834 65 75 2 (0.217%)
Fetal brain Abnormality of the forebrain HP:0100547 213 640 276 (29.9%)
Fetal heart Abnormality of the heart HP:0001627 273 491 236 (25.6%)
Fetal intestine Abnormality of the intestine HP:0002242 121 260 17 (1.84%)
Fetal kidney Abnormality of the kidney HP:0000077 184 383 77 (8.35%)
Fetal lung Abnormality of the lung HP:0002088 149 529 9 (0.976%)
Fetal muscle Abnormality of the musculature HP:0003011 667 1079 291 (31.6%)
Fetal stomach Abnormality of the stomach HP:0002577 24 116 10 (1.08%)
Fetal thymus Abnormality of the thymus HP:0000777 9 26 0 (0.0%)
White blood cells Abnormality of leukocytes HP:0001881 195 256 4 (0.434%)
For each tissue type, a corresponding HPO term was chosen, and CNV cases were assigned to the HPO term if the term itself or any of its descendant terms was used
to annotate the CNV in the DECIPHER database (See Materials and methods for details). The column ‘Genes’ shows the number of genes associated with monogenic
diseases that display the corresponding feature in the main HPO database. The column ‘Cases’ shows the number of individuals in the 922 DECIPHER deletions
investigated in this work that were annotated to have the HPO term in question. CNV, copy-number variation/variant; HPO, Human Phenotype Ontology.
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considered to be adjacent to the deletion if it was located
between the deletion breakpoint and the distal end of the
affected topological domain (Figure 1).
In all, 4.45% of the CNVs from the DECIPHER dataset
were assigned to the TDBD category, and an additional
2.28% were assigned to both TDBD and GDE (Figure 4A).
Therefore, our results suggest that there may be a contri-
bution of dysregulation of phenotypically relevant genes
by disruption of TDBs in up to 6.72% of the DECIPHER
deletions, compared to 75.7% with evidence only for GDE.
Finally, for 17.6% of the cases, no phenotypic informa-
tion for the genes within the deletions was available that
matched the CNV phenotypes.
For comparison, we then performed an analysis of ran-
domized data, whereby the deletion was assigned ran-
domly to a different phenotypic category from Table 2.
For instance, a deletion originally assigned to Abnormal-
ity of the forebrain might be assigned to Abnormality
of the kidney. We then tried to identify the best ‘expla-
nation’ for the random phenotype as GDE or TDBD as
described above. Since the phenotypic spectrum of CNVs
is complex and often multiple organs are affected, it is
not surprising that some matches are found, but we rea-
soned that if the signal we observed for TDBD events in
the real data was genuine, a lower proportion of random
deletions would be placed into this category. In fact, there
were significantly fewer deletions assigned to the category
TDBD (P = 8 × 10−4; Figure 4B). As an additional back-
groundmodel, we permuted the phenotype annotations of
all human genes and found similar enrichment of TDBD
deletions in the real data compared to randomized back-
ground (P = 0.003; Figure 4B). The larger a deletion is,
the more likely it is to contain haplosensitive genes whose
deletion will cause a phenotype, whereas the chance that
a deletion primarily acts by the TDBD mechanism should
only depend on the enhancers and genes located adja-
cent to the deletion, and thus should not be dependent
on the size of the deletion. Therefore, we investigated
the relation between the number of topological domain
boundaries affected by a CNV and the frequency of TDBD
effect mechanisms. These data show that small deletions
that overlap only one boundary show rates of 10% TDBD
and thereby higher frequencies than larger deletions that






























Figure 4 Phenotype explanation of 922 CNVs as GDE or TDBD. (A) Counts of DECIPHER deletions classified as GDE or TDBD. It was found that 41
of the TDBD cases did not demonstrate computational evidence of GDE and are indicated as TDBD only in (B). (B) Proportion of CNVs predicted to
correspond to TDBD, GDE or both, compared with randomized data by permutation of phenotype annotations of the DECIPHER patients (green)
and permutations of phenotype associations of genes to monogenic diseases (purple). 6.72% of the deletions in the DECIPHER cases were predicted
to be TDBD or mixed TDBD/GDE, compared to 5.18% on average for randomized (phenotype-shuffled) deletions (P = 0.0008) and 4.88% for
randomizations with permuted gene phenotypes (P = 0.003). A pure TDBD mechanism was predicted for 4.45% of the DECIPHER cases and a mean
of 2.84% of the randomizations with permuted CNV phenotypes (P < 0.0001), and in 3.02% with permuted gene phenotypes (P = 0.014). ‘No
boundary enhancer adoption’ refers to deletions that do not overlap a boundary element but have a matching enhancer and gene signature in the
400-kb flanking regions. Here no significant enrichment over randomized data was observed, suggesting that the disruption of chromatin
architecture contributes to TDBD-related enhancer adoption. CNV, copy-number variation/variant; GDE, gene-dosage effect; kb, kilobase; TDBD, TDB
disruption.
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deletions that overlap up to three TDBs, the frequency of
TDBD events was significantly higher in the DECIPHER
CNV cases than in the randomized data with permuted
CNV phenotypes (one TDBD: P = 0.01; two TDBDs:
P = 0.0014; three TDBDs: P = 0.0036; Additional file 1:
Figure S3).
An alternative hypothesis to our concept of TDBD is
simply that enhancer adoption occurs solely because a
deletion brings a tissue-specific enhancer into the vicin-
ity of a tissue-specific gene, regardless of chromosomal
domains. The question boils down to whether TDBs tend
to separate tissue-specific enhancers whose effect on phe-
notypically relevant genes would otherwise have a dam-
aging effect. It would be difficult to provide a conclusive
computational answer to this question for any specific
CNV without extensive experimental validation. How-
ever, we did address the question by analyzing the 253
DECIPHER deletions that do not overlap any TDB. To
do so, we searched in windows of 400 kb for the match-
ing enhancer and gene signature on both sides of these
deletions. We chose a distance of 400 kb because it cor-
responds to the median observed distance of 389.9 kb
between CNV breakpoints and the next closest TDB (or
in some cases the end of the chromosome or a region
of unorganized chromatin at the border of a domain).
Only 1.63% of the 922 DECIPHER deletions fulfilled our
enhancer adoption criteria without overlapping a bound-
ary element (Figure 4, right panel). This proportion is not
more than expected from randomized data with permuted
CNV phenotypes (1.44%, P = 0.33) or permuted gene
phenotypes (2.02%, P = 0.86), which therefore suggests
that the disruption of chromatin architecture by TDBD is
a major factor in the enhancer adoption mechanism.
As a control for the specificity of enhancers, we repeated
the TDBD analysis with the ubiquitous DHS and observed
lower rates of TDBD events compared to the analy-
sis with tissue-specific enhancers (3.69% for ubiquitous
vs 4.45% for tissue-specific enhancers; Additional file 1:
Figure S4A). Furthermore, the phenotypic similarity of
genes adjacent to the deletion to the phenotypes of the
patient was significantly higher for TDBD with tissue-
specific enhancers compared to the ubiquitous enhancers
(P = 0.013; Additional file 1: Figure S4B).
Model organism data increases the number of
interpretable copy-number variants
We recently presented an ontology-based approach to
measure similarities between human disease manifesta-
tions and the mutational phenotypes in model organ-
isms to identify candidate genes located within CNVs
that best explain the individual phenotypic features of
the CNV [29]. Since there are considerably more mouse
and zebrafish mutants with monogenic defects than the
number of currently characterized Mendelian diseases
of humans [30], we asked whether cross-species analy-
sis would increase the percentage of CNVs that could be
classified with our algorithm. As in our analysis of purely
human disease data, we compared the similarity of the
2,300 DECIPHER deletion phenotypes to the phenotypes
of the single-gene disorders of the genes located within the
CNVs. However, here, we used the cross-species ontology
Uberpheno [31] to exploit mouse and zebrafish annota-
tions for these genes. The phenotypic similarity for the
DECIPHER deletions was significantly higher than for
randomized deletions (62.2±81.8 compared to 45.6±66.8;
P = 2.36 × 10−58). Using the cross-species data, we again
analyzed the 922 DECIPHER deletions that had been
assigned to a target phenotype corresponding to a tissue-
specific enhancer. Compared with the purely human data,
about 10% more cases could be classified for a total of
92% of all CNVs for which our phenotypic analysis allowed
assignment to one of the categories TDBD and GDE.
Compared to the rate of 4.45% TDBD events predicted
with human data, 5.75% of deletions were characterized
as purely TDBD using the model organism data. This was
significantly more than for randomized data with per-
muted CNV phenotypes (P = 0.011) and permuted gene
phenotypes (P < 0.001; Additional file 1: Figure S5).
DECIPHER deletionswith predicted TDBDpathomechanism
We identified three patients with TDBDs at the FOXG1
locus (Figure 5A). Mutations in FOXG1 itself cause a con-
genital variant of Rett syndrome [32,33]. The patients
with a TDBD at the FOXG1 locus show severe Rett-like
phenotypes similar to patients carrying FOXG1 muta-
tions. A recent study [34] showedmisregulation of FOXG1
in cell lines derived from patients with such deletions
and proposed misregulation of FOXG1 rather than hap-
loinsufficiency of the gene contained within the deletion
(PRKD1) as the primary pathomechanism. The authors
suggested that a cis-acting regulatory sequence located
in the deleted region more than 6 kb away from FOXG1
might act as a silencer element at the transcriptional level.
Our data, however, suggest that the deletions remove
TDBs and bring ectopic fetal brain enhancers into the
regulatory landscape of FOXG1. As shown in Figure 5A,
several brain enhancers, including the enhancer element
hs433, are located close to the breakpoint and are now
free to act on FOXG1 to cause misexpression in the brain
of the affected individuals [35]. This mutation mechanism
has also been described as enhancer adoption [36] and
transgenic studies show that individual enhancer elements
cloned in front of their ectopic target genes are able to
recapitulate disease phenotypes in mice [20]. Therefore,
we suggest that misexpression of FOXG1 in the patients
with the congenital variant of Rett syndrome can be bet-
ter explained by TDBD than by a deletion of a silencer
element.
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Figure 5 DECIPHER CNVs whose pathomechanism can be explained by TDBD. (A) Candidate TDBD at the FOXG1 locus. Three of the 40
candidate TDBD cases identified in this study are located adjacent to the FOXG1 gene. They are truncating mutations associated with
neurodevelopmental phenotypes such as Rett syndrome [32]. All these microdeletions overlap the gene PRKD1 and a topological boundary region
but not FOXG1 itself. Human element hs433 is shown as an image from the VISTA enhancer browser [37]. (B) A deletion of about 3.9 Mb on
chromosome 10 leads to haploinsufficiency of a number of genes with no known phenotypic relevance to the CNV phenotype ofmultiple renal cysts
(HP:0005562). The deletion also removes a total of five TDBs that lie between several predicted kidney-specific enhancer elements and the gene
FGFR2. chr14, chromosome 14; CNV, copy-number variation/variant; kb, kilobase; Mb, megabase; TDB, topological domain boundary; TDBD, TDB
disruption; UCSC: University of California, Santa Cruz Genome Browser.
A deletion of about 3.9 Mb on chromosome 10 leads to
haploinsufficiency of a number of genes with no known
phenotypic relevance to the CNV phenotype of multi-
ple renal cysts (HP:0005562). The deletion also removes
a total of five TDBs that lie between a predicted kidney-
specific enhancer at chr10:118,480,800 to 118,481,000 and
the gene FGFR2. Many fibroblast growth factors (FGF)
and all of their receptors (FGFR) are expressed in the
developing kidney, and overexpression of basic fibroblast
growth factor in developing rodent kidneys can induce
the formation of renal cysts in vivo [38]. In humans, acti-
vating and loss-of-function mutations in FGFRs cause
syndromes that are sometimes associated with urogenital
anomalies [39], including lacrimo-auriculo-dento-digital
syndrome and Antley–Bixler syndrome, both of which
can be caused by FGFR2mutations and in some cases are
associated with severe congenital renal anomalies [40,41].
Therefore, we hypothesize that disruption of the TDBs in
the deletion in DECIPHER case 262197 results in overex-
pression of FGFR2 in the developing kidney with resultant
formation of renal cysts (Figure 5B).
Two additional cases (not shown in Figure 5)
showed deletions in the vicinity of the DUX4 gene.
Facioscapulohumeral muscular dystrophy is an autosomal
dominant disease associated with reduction in the copy
number of the D4Z4 repeat at chromosome 4q35. The
reduction in D4Z4 copy number leads to reduced poly-
comb silencing and production of a chromatin-associated
non-coding RNA that coordinates derepression of 4q35
genes including the transcription factor DUX4 [42]. The
resulting misexpression of DUX4 in skeletal muscle may
be associated with apoptosis of muscle cells [43,44]. A
similar D4Z4 repeat array, which contains a paralog of
DUX4 at chr10:135,480,558 to 135,485,241, has been
identified on chromosome 10q26, but contractions at the
10q26 locus are not pathogenic. DECIPHER case 249776
represents a deletion of chr10:130,955,710 to 135,397,841.
The deletion removes two TDBs thereby bringing 107
muscle-specific enhancers into the vicinity of the chromo-
some 10 DUX4 paralog. Similarly, DECIPHER case 4069
represents a deletion at chr10:129,690,073 to 135,422,505,
which removes three TDBs and brings 33 muscle-specific
enhancers into the vicinity of the chromosome 10 DUX4
paralog. Both DECIPHER cases are associated with a
number of features including muscular hypotonia, which
was the feature leading to the characterization of the
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deletion as TDBD. Therefore, one possibility for the
pathogenesis of this feature might be an inappropriate
activation of the chromosome 10 DUX4 gene by adoption
of the muscle-specific enhancers.
Additional file 1: Table S2 provides an overview of the
41 DECIPHER CNVs classified as purely TDBD by our
algorithm.
Conclusions
In this work, we have provided suggestive computational
evidence that a TDBD pathomechanism may be involved
in a substantial minority of deletions recorded in the
DECIPHER database. For the great majority of deletions
and other CNVs identified to date, medical interpreta-
tion (‘explanation’ of the phenotypic features found in an
individual with the CNV) has been based on a guilt-by-
association approach, in which one compares the CNV
phenotypic features with those associated with mono-
genic diseases of the genes located within the CNV. Thus,
the explanation of the phenotypic feature supravalvu-
lar aortic stenosis in WS is thought to be haploinsuf-
ficiency of the elastin gene, because individuals with
loss-of-function mutations in this gene have the identi-
cal phenotypic abnormality. Comprehensive experimental
investigation of the pathomechanism of a CNV disease
such as WS might involve the generation of mouse mod-
els in which the orthologous chromosomal regions have
been removed but each of the genes in turn is ‘res-
cued’ by addition of a corresponding transgene construct.
Since strategies such as this are currently unthinkable for
investigating the pathogenesis of human CNV diseases,
numerous computational approaches have been applied
to investigate the pathogenesis of CNVs [29,45-48]. In
the current work, we have shown that a computational
approach to analyze deletions in light of adjacent tissue-
specific enhancers and genes identifies up to around 10%
of deletions in DECIPHER as having a potential contribu-
tion of the TDBD pathomechanism. While our approach
does not provide proof of this pathomechanism, previ-
ous guilt-by-association approaches did not do so either.
Our results do suggest that TDBD should be taken into
account in the interpretation of deletions, and that cor-
responding experimental analysis of deletions may be
fruitful for future research.
A limitation of our study is the fact that the size of
deletions in DECIPHER (mean 3.68 Mb) is much greater
than the mean distance between adjacent TDBs. In con-
trast, the deletions we identified in two individuals with
Liebenberg syndrome were only 134 kb and 107 kb in
size [20]. The larger deletions that are common in DECI-
PHER are more likely to have a complex mode of patho-
genesis resulting from haploinsufficiency of one or even
multiple genes located within the deletion and in some
cases at least from the enhancer adoption mechanism
[21]. However, we speculate that there may be a bias
to submit cases with large CNVs to databases such as
DECIPHER, because previous paradigms of CNV inter-
pretation focused on a potential phenotypic relevance
of genes located within the CNV itself, not on adjacent
genes [49]. Therefore, it may be fruitful for future research
to search specifically for smaller deletions that conform to
the enhancer adoption pathomechanism described here.
We did not analyze duplications in our study. The loca-
tion of duplicated copy can be adjacent to the original
(tandem) or somewhere else in the genome, and a tandem
duplication can be in the original orientation or inverted.
Array CGH, which was used to generate the data investi-
gated in our study, is not able to distinguish between these
possibilities, each of which would be predicted to have a
different effect on gene regulation by disruption of TDBs.
However, a duplication could in principle bring elements
that are normally separated by one or more TDBs into the
vicinity of one another and thereby cause disease.
Our results have important implications for the medi-
cal and scientific interpretation of CNVs, and suggest that
the pathomechanism of a sizable minority – up to even
11.8% – of CNVsmay be related to the disruption of TDBs
with misregulation of phenotypically relevant genes due
to enhancer adoption. Currently, medical interpretation
of rare CNVs often involves comparison of the phenotype
seen in the patient with the CNV with that of mono-
genic diseases associated with genes located within the
CNV.Our results suggest that it is also important to exam-
ine the topological domain structure in the region of the
CNVs for the presence of tissue-specific enhancers and
phenotypically relevant genes that lie adjacent to the CNV
itself. It will also be important to develop experimental
strategies for investigating these cases based on chro-
mosomal conformation capture or similar approaches.
Finally, the analysis described in this paper was made
possible because of data shared by many in the commu-
nity within the framework of the DECIPHER database,
demonstrating the value of sharing genotype and pheno-
type information with appropriate data access conditions.
Phenotypic data will continue to be key to understanding
the medical relevance of genomic variation.
Materials andmethods
Clinical andmolecular copy-number variant data
The DECIPHER database is an online repository of rare
genomic CNVs and associated phenotypic data [22]. For
each of the 7,535 cases in DECIPHER, we considered only
the single largest CNV, of which 4,055 were deletions.
Of these, 2,300 were annotated with phenotypic data and
were used for our analysis. We additionally compiled a set
of CNVs from 5,919 individuals participating inWTCCC2
as common controls as previously described [45]. After
mapping the genomic coordinates to the hg19 reference
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genome using the UCSC liftover tool [50], we again took
only the largest CNV per case into account and analyzed
only deletions. Our underlying assumption with this data
is that CNVs observed among adults recruited as con-
trols for genome-wide association studies are unlikely to
be causative of congenital anomalies.
Tissue-specific enhancer prediction
DNase-seq is a high-throughput experimental technol-
ogy, which has been shown to be effective in identifying
open chromatin regions that correspond to active gene
regulatory elements. Nucleosome-depleted regions rep-
resenting open chromatin are distinguished from DNA
regions that are tightly wrapped in nucleosomes or in
higher-order structures by the ability of DNase I to digest
the sequences. DNase-seq identifies such DHSs by cap-
turing DNase-digested fragments and sequencing them
by next-generation sequencing [51]. Transcription factor
binding is highly cell-type specific, and the investigation
of differential DNase I hypersensitivity provides a gen-
eral approach for predicting cell-type specific binding
profiles [52]. In this work, we have developed a compu-
tational methodology to predict tissue-specific enhancers
on the basis of differential DNase I hypersensitivity pro-
files from ten human tissues (Table 2). Accessible chro-
matin regions are preferentially cleaved by endonucleases,
such as DNase I, and are therefore referred to as hypersen-
sitive, and can be measured using DNase-seq by digesting
chromatin with the endonuclease DNase I followed by
next-generation sequencing. DNase-seq thus generates a
genome-wide map of DHSs that reflects the degree to
which sequence regions were accessible [53].
DNase-seq reads from the NIH REMC [54] were
counted in 200-bp windows covering the human genome.
Windows that overlapped repetitive elements in Repeat-
Masker with scores higher than 1,000 were eliminated
leaving 9.7 million windows. Genomic range manipula-
tion and counting were performed using BEDTools [55].
The logs of the counts plus a pseudocount of one were
normalized for sequencing depth by multiplying each
sample by the average read count over all samples divided
by the sample’s average read count. For each sample, we
counted the number of DNase-seq reads falling into non-
overlapping 200-bp windows along the human genome
excluding strong repeat sequences. After accounting for
different sequencing depth in the samples, we generated
an average profile for each tissue as well as for all tissues
combined (ubiquitous DHS) (Figure 3). Using correlation
to measure distance between DNase profiles, we were able
to group samples by cell type with hierarchical cluster-
ing (Figure 3B). The differences for each 200-bp window
and each tissue from the average profile were calculated
and weighted by the pooled within-tissue standard devi-
ation. This derived quantity corresponds to a t-statistic
and measures the specificity of a DHS for the correspond-
ing tissue. We then ranked all the 200-bp windows for
each tissue such that top-ranked sites corresponded to the
largest positive t-statistics.
We have shown that our quantitative measure of tissue
specificity allows us to define a reproducible set of ranked
DHSs. Next, we tested whether the location and the chro-
matin environment of the identified CTS-DHSs support
our claim that the identified CTS-DHSs are indeed spe-
cific for a tissue or cell type. The top CTS-DHSs are
located primarily in intronic and intergenic regions. This
is in stark contrast to the top ubiquitous DHSs, of which
72% overlap promoter regions (Figure 3). These findings
suggest that the CTS-DHSs are mainly enhancers, which
may regulate nearby genes – a conclusion that has also
been drawn in earlier studies about cell lines [23-25].
We used the profiles of the normalized log counts from
each DNase-seq sample to find regions of similarity and
difference across the tissue types. We created an average
profile of DNase accessibility for each tissue type as well
as across all tissue types (ubiquitous DNase hypersensi-
tive sites). We then predicted tissue specificity based on
a calculation of the within-tissue-type variance of DNase
accessibility.
For a given window, let Xi be the log read count for
sample i ∈ {1, . . . , n}. We denote the set of all samples
belonging to a given tissue type j ∈ {1, . . . ,m} as Cj, i.e.,
Cj ⊆ {1, . . . , n}. Note that in our work we assume that
each sample i belongs to exactly one tissue type, that is,
the Cj are pairwise disjunct. If we denote the the cardi-
nality of Cj as nj, the average log read count for sample
j is Xj = 1nj
∑
i∈Cj Xi, and thus the average log read
count for the ubiquitous DHS is X = 1m
∑m
j=1 Xj. Further-




i∈Cj(Xi − Xj)2. Assuming equal variance among




















For tissue type j, the t-statistic is calculated as:
tj = Xj − X√1/m + 1/nj · (s + s0) , (2)
where s0 is the mean of s over all windows to prevent divi-
sion by small within-cell-type variance estimates [56]. The
ranking of these t-statistics over all windows was used to
quantify the cell-type specificity. Statistical analysis was
carried out using the R statistics environment, using the
sparse matrix package Matrix.
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To estimate the number of reproducible top-ranked
DHSs, all DNase-seq samples were split into two equally
stratified groups. Then, within-cell-type standard devia-
tions and CTS-DHSs were calculated separately for each
group. For the top n sites, the reproducible ratio (the
proportion of top CTS-DHSs that are shared between
the two groups) was calculated. Looking at reproducible
ranks (correspondence at the top plots) helps to deter-
mine at what cutoff the ranks transition from consistent
ones into lower ranks dominated by noise [57,58]. Max-
ima were defined using interpolation of reproducible ratio
curves (Additional file 1: Figure S1 and Additional file 1:
Table S1).
Topological domains and boundaries
Topological domain data from genome-wide higher-order
chromatin interaction data in human embryonic stem
cells [12] were downloaded [59] and mapped to hg19
coordinates using the UCSC liftover tool [50]. TDBs are
defined as regions with size up to 400,000 bp (400 kb)
between topological domain regions.
Analyzing phenotypic similarity: human phenotype
ontology and the Uberpheno ontology
The data for the analyzed CNV patients in the DECIPHER
database are annotated with a set of phenotype terms from
HPO. For each HPO term t, the information content IC(t)
is calculated as the negative logarithm of the frequency of
annotations to the term [60]:
IC(t) = − log pt , (3)
where pt is the observed frequency of patients annotated
to term t among all annotated patients in DECIPHER,
pt = patients with term tall patients . Note that the annotation propaga-
tion rule applies here [61], i.e., if a patient is annotated to a
term t then the patient is also annotated to all of the more
general terms.
For some of the analyses described in this work, we
assigned patients to one of ten phenotypic categories
corresponding to the ten tissue-specific enhancers. This
strategy was based on observations in families with PITX1
mutations and for Liebenberg syndrome. The transcrip-
tion factor Pitx1 is expressed predominantly in the devel-
oping hindlimb and is only minimally expressed in the
forelimb [62], suggesting that Pitx1 is an important reg-
ulator of hindlimb identity. Both a missense mutation
in the highly conserved homeodomain of PITX1 as well
as a 241-kb chromosome 5q31 microdeletion have been
shown to result in clubfoot in humans [63,64], allow-
ing PITX1 to be assigned to the top-level category of
genes with phenotypic relevance for the skeleton. In our
previous work, we showed that heterotopic activation
of Pitx1 by tissue-specific skeletal (forelimb) enhancers
leads to Liebenberg syndrome [20,21]. We note that the
phenotypic features of these diseases are distinct (club-
foot with PITX1 mutations and an upper-limb malfor-
mation in Liebenberg syndrome), but that they both
affect the skeletal system. Therefore, we reasoned that
if heterotopic activation of a gene by a tissue-specific
enhancer is responsible for a CNV phenotype, then we
should expect a phenotypic abnormality in the same
organ system rather than necessarily an exact phenotypic
match.
Therefore, we let T = {T1,T2, . . . ,T10} represent
the ten HPO terms shown in Table 2, annotj ={
tj1 , tj2 , . . . , tjm
}
be the m terms to which patient j is
directly annotated, and desc(Ti) represent all terms that
are more specific descendants of term Ti as well as the
term Ti itself. With Sij = desc(Ti) ∩ annotj, patient j was






We only included cases in the further analysis if they
had at least one term in Sij and for which there was a
unique maximum for one of the ten Ti. Then 922 of
the 2,300 deletion cases could be assigned to one of the
ten phenotype categories in Table 2 in this fashion. The
remaining cases could not be classified because they did
not share phenotype terms with any of the target terms
(n = 1, 377). One case was excluded from further analysis
because maximal values were obtained for more than one
target term by Equation 4.
Quantification of phenotypic similarities
The genomic coordinates of human genes in hg19 were
retrieved from the UCSC known-genes table and mapped
to Entrez Gene IDs. For the resulting 23,459 genes,
only the longest transcript was considered. The similarity
between the set of phenotype terms annotj used to anno-
tate a patient j and the set of terms associated with genes
in the genomic region within or adjacent to a deletion is
calculated as described previously [29] with some mod-
ifications. For each gene g in a region GCNV within or
adjacent of a deletion, a phenomatch score Sg is defined
based on the information content of the term. For these
calculations, the frequencies pt were calculated based on
HPO project annotations for human diseases [65]. For
cross-species analyses, the frequencies pt were calculated
based on annotations to term t amongst all annotated
genes in humans, mice and zebrafish in the cross-species
phenotype ontology Uberpheno [31].
We define anc(T) as a function that for a given term or
set of terms, returns the set of ancestral terms. The set of
common ancestors of term tg associated with gene g (tg)
Ibn-Salem et al. Genome Biology 2014, 15:423 Page 13 of 16
http://genomebiology.com/2014/15/9/423
and the set of terms associated with the deletion observed
in DECIPHER patient j (annotj) is defined as
CA(tg , annotj) = anc(annotj) ∩ anc(tg). (5)
We can now define the phenotypic similarity of an indi-





max{IC(t)|t ∈ CA(tg , annotj)}.
(6)
Finally, the full phenogram score across all genes located
within the CNV is calculated as the maximum of the
phenomatch scores Sg of all genes within the CNV:
SPG(Gcnv, annotj) = maxg∈Gcnv Sg(g, annotj). (7)
An analogous score is calculated for the genes that are
adjacent to the CNV:
SPG(GAdj, annotj) = maxg∈GAdj Sg(g, annotj). (8)
We note that in our previous work [29], we used a scor-
ing scheme designed to identify all genes within the CNVs
that were good candidates for contributing to the phe-
notypic spectrum of the CNV. This was possible because
of our detailed manual biocuration of the 27 CNV syn-
dromes. For the current project, we chose a scoring sys-
tem that would look for a single gene within or adjacent
to the CNV with the maximal phenotypic similarity, since
the depth of annotations in DECIPHER is much less.
Statistical analysis
To test whether the phenogram score in Equation 7 cap-
tures clinical similarities between deletions and the genes
located within them (as with the ELN gene and WS as
explained in the introduction), we placed each of the 2,300
DECIPHER deletions with at least one HPO term 100
times randomly on the genome and compared the distri-
bution of phenogram scores of genes within the random
deletions against those of the DECIPHER deletions with a
Wilcoxon/Mann–Whitney test.
For a given patient assigned to the phenotype target
term T , we define a deletion as TBDB, if it completely
overlaps a TDB, has a T-specific enhancer in one region
adjacent to the CNV and has a gene associated with T in
the adjacent region located on the other side of the CNV.
Adjacent regions span the genomic sequence from each
end of the deletion up to the end of the current domain
(Figure 1B).
To assess the statistical significance of TBDB events in
DECIPHER, we simulated a background distribution by
permuting the phenotype annotations in the following
way. We assigned to each DECIPHER patient i the pheno-
type annotation of a randomly chosen DECIPHER patient
j that is not in the same target term group as the original
patient i. We repeated this procedure for all 922 deletion
patients 10,000 times and computed the empirical P value
as the fraction of randomizations for which a higher or
equal rate of TBDB events as in the original annotation
assignment is observed. As a further control, we permute
the phenotype annotations not of the CNV patients but of
the genes. To do so, we shuffled all 23,459 human gene IDs
randomly and replaced each gene in the HPO annotation
files with a random other gene. This approach to permu-
tation holds the number of disease genes and depth of
annotation constant. We computed an empirical P value
as the proportion of 1,000 permutations in which a higher
or equal rate of TBDB events was observed compared with
the non-permuted gene phenotypes.
Data and code deposition
Python scripts that implement the algorithms described
in this manuscript have been deposited in GitHub [66].
This repository also contains files with data on the tissue-
specific enhancers used in this analysis. Additionally,
source code for performing simple statistics on sparse
data sets without losing sparsity that was used for the
analysis of tissue-specific enhancers has been deposited
as SparseData in GitHub [67]. The phenotypic data on
patients with CNVs were obtained from the DECIPHER
consortium [22]. The DECIPHER website offers informa-
tion on how researchers can obtain access to this data [68].
It is also possible to visualize individual deletions in the
UCSC Genome Browser [69]. For example, the dele-
tion chr19:30682288 to 36367331 (which is the second
entry in Additional file 1: Table S2) can be visualized
by selecting the human genome assembly of February
2009 (GRCh37/hg19) in the UCSC Browser, entering the
search term ‘chr19: 30682288-36367331’, and then set-
ting the DECIPHER track in the section Phenotype and
Literature to full, and clicking the refresh button. The
individual in question has the id DECIPHER:3776, and
by letting the mouse hover over the red bar next to the
number 3776 in the browser, the corresponding pheno-
type terms will be shown. It is not currently possible to
download all DECIPHER data from the UCSC Genome
Browser.
We used the latest version of the DECIPHER data from
5 April 2013 with 7,535 patients. The patient IDs are rep-
resented by increasing numbers and the last patient we
analyzed has the ID 273601. The HPO and Uberpheno
data are publicly available from the HPO download page
[70]. For the analysis described here, we used OBO files
and annotation tables fromHPO build #856 (9 December
2013) and build #132 (9 December 2013) of the cross-
species ontology Uberpheno.
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